Navigation Links
Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality

ENGLEWOOD, Colo., Nov. 16, 2010 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today announced significant upgrades to its DoseEdge Pharmacy Workflow Manager.  DoseEdge is the only pharmacy workflow management tool that verifies the use of correct drugs, diluents and concentrations in the compounding of IV, chemo, TPN and oral liquid doses.  This release includes more than 39 improvements and functionality enhancements.

DoseEdge has achieved a major milestone in the advancement of sterile dose compounding, having processed more than 5 million safe doses since its market introduction.  Through barcode verification of every drug ingredient, DoseEdge has prevented more than 100,000 preparation errors.  With this release, version 2010.2 of the software, users can now extend DoseEdge safety benefits to a wider variety of compounded dose types through the application of a greatly expanded formulary database.  To view technical videos or download educational materials on DoseEdge, visit

Improvements and new functionality added to the DoseEdge Pharmacy Workflow Manager in version 2010.2 include:

  • FormularyPlus™ – Allows DoseEdge to identify more than 14,000 drug products via barcode scanning, and provides a process for easy maintenance and adding new products as information becomes available.
  • Oral Liquid Dose Types – The addition of 9,000 new drug products to the formulary database extends DoseEdge safety benefits to the preparation of unit-dose oral liquids, with cost benefits for users of the Baxa ExactaMed® line of oral syringes.
  • Improved Overfill Handling – DoseEdge uses concentration data provided by the Pharmacy Information System to calculate dose volumes and verify correct product concentrations when an overfill volume is specified.
  • Improved Email Alerts – Notifications have been added that will alert pharmacists that doses are available for remote verification.
  • New Windows Support – DoseEdge now supports Windows 7 Professional on all PrepStations™ and Windows Server 2008 for Local Cache Servers.

  • "DoseEdge is the only dose management software that delivers compounding workflow management and error prevention for such a wide variety of dose types.  Hospitals across the country use DoseEdge to make thousands of safe doses every day," said Larry Gibson, product manager at Baxa Corporation.  "Today's updates enable Directors of Pharmacy to manage pharmacy operations more easily and better utilize their teams to fulfill IV and oral drug preparation demands."

    To view a live demonstration of the DoseEdge Pharmacy Workflow Manager, visit Baxa Corporation in booth #1841 at the ASHP Midyear Clinical Meeting & Exhibition (ASHP), December 5-9th in Anaheim, California.  

    To hear first-hand experiences direct from DoseEdge users, attend an exclusive exhibitor's theatre symposium at ASHP, The Power of Control: Using pharmacy software tools to get control of your workflow, ensure quality control and support patient safety initiatives.  For more information, visit

    For more information about Baxa and its industry-leading IV automation products, e-mail or visit

    About Baxa CorporationBaxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications.  Key products include the Abacus® Order Entry and Calculation Software, the DoseEdge™ Pharmacy Workflow Manager, ExactaMed® Oral Syringes, ExactaMix™ Automated Compounding Devices, InFuse™ and MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, NeoThrive® Enteral Syringes, the PadLock®  Set Saver and the RapidFill™ and IntelliFill® i.v. Automated Syringe Fillers; used worldwide in hospitals and healthcare facilities.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at Robinson, Vice President, MarketingBaxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157Email:  marian.robinson@baxa.comPerrin McCormick or Brandie GerrishHB | Hart-Boillot: 781-893-0053Email:

    SOURCE Baxa Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
    2. CEL-SCI Corporation Releases Letter to Shareholders
    3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
    4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
    5. Immunosyn Corporation Releases SF-1019 Study Results
    6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
    7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
    8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
    9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
    10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
    11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
    Post Your Comments:
    (Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
    (Date:11/25/2015)... N.Y. , Nov. 25, 2015  Linden Care, ... and optimizing treatment outcomes for patients suffering from chronic ... request for a Temporary Restraining Order (TRO) enjoining Express ... the two companies. --> ... pursuing all of its legal options. ...
    (Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
    Breaking Medicine Technology:
    (Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... the possibilities are endless. Users have full control over angle of view, speed method, ... users are sure to get heads to turn. , ProPanel: Pulse offers fully customizable ...
    (Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... out by the University of Toronto and the University of British Columbia suggested that ... for head injuries. The article explains that part of the reason for the controversial ...
    (Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
    (Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
    (Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that ... ). More than 3.7 billion people under the age of 50 – or 67% ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
    Breaking Medicine News(10 mins):